

## Index to Volume 26

Index of Issues: January, 1-66; February, 67-120; March, 121-190; April, 191-242; April Supplement, S1-S52; May, 243-308; July, 309-368; August, 369-420; September, 421-490; October, 491-548; November, 549-608

## INDEX OF AUTHORS

- A**
- Abdool Karim SS, 152  
 Adler N, 208  
 Alary M, 317, 410  
 Ali-Napo L, 191  
 American Social Health Association  
 Panel, S2  
 Anglin MD, 82  
 Aral SO, 262  
 Aramburu J, 103  
 Artz L, 127, 450  
 Ashley R, 221  
 Augenbraun M, 143  
 Austin H, 127, 329, 450  
 Avgerinou H, 43
- B**
- Bacchetti P, 143  
 Bachmann L, 87, 272, 496  
 Baer JT, 335  
 Ballard RC, 556  
 Barkan S, 143  
 Barker K, 508  
 Baseman J, 444  
 Bastani R, 463  
 Beauchamp D, 177  
 Beckham C, 213  
 Beebe JL, 579  
 Benedetti J, 221  
 Bensen C, 364  
 Bergeron MG, 177  
 Berglund T, 390  
 Bernier F, 410  
 Bernstein DI, 438  
 Beutner K, 364  
 Biro FM, 472  
 Blackwelder T, 137  
 Blythe MJ, 26  
 Bock JE, 325  
 Boisvert J-F, 392  
 Bolan G, 335  
 Bollinger R, 55  
 Bonard D, 191  
 Bonney MS, 49  
 Borthagaray G, 157  
 Boyd MA, 543  
 Brewer DD, 166  
 Brizendine EJ, 26  
 Buchbinder S, 564  
 Bull SS, 584  
 Burns D, 143
- C**
- Caceres CF, 103  
 Carey RF, 216  
 Casabona J, 500  
 Castellano T, 103  
 Castello Daly C, 381  
 Cates W Jr, 459, S2
- C**
- Celum CL, 564, 572  
 Chakraborty H, 381  
 Chan RKW, 593  
 Chan-Tack K, 55  
 Chernesky M, 504, S8
- C**
- Chesney MA, 572  
 Chou C-P, 82  
 Chua WL, 593  
 Clemens CM, 160  
 Cohen MS, 381  
 Cohen SS, 472  
 Cole PA, 87  
 Coles FB, 296  
 Coletti AS, 564, 572  
 Combe P, 191  
 Conant M, 364  
 Conrad N, 527  
 Contento KM, 335  
 Coplan PA, 184  
 Corey L, 1, 221  
 Cormier H, 177  
 Coronado N, 543  
 Coughlin S, 108  
 Creede P, 579  
 Crosby RA, 399  
 Cullen AP, 303  
 Cyr WH, 216
- D**
- Dallabetta G, S12  
 Dalu ZA, 531  
 Davis G, 364  
 Delapenha R, 143  
 DeLisle S, S28, 339  
 Désormaux A, 177  
 DeVellis RF, 472  
 Dhéha D, 191  
 Diamond C, 221  
 Divekar A, 55  
 Divekar AA, 358  
 Dobbins JG, 67  
 Dorst D, 281  
 Dosso M, 191  
 Dufour A, 317  
 Dunlop MBV, 208
- E**
- Ellen JM, 208  
 Ellish N, 75  
 Eubanks C, 537  
 Everett W, S49  
 Ewell J, 201
- F**
- Farley TA, 108, 201  
 Faxelid E, 491  
 Faye-Ketté H, 191  
 Fenner DE, 137  
 Fife KH, 226  
 Finch M, S23  
 Fleenor M, 127, 329, 450  
 Flemetakis A, 43  
 Fleming TR, 564  
 Foglia G, 421  
 Ford JA, 87  
 Ford K, 17  
 Forman P, 556  
 Fortenberry JD, 26, 584  
 Frangouli E, 43  
 Fredlund H, 390  
 Fresia A, 75
- G**
- Gadkari D, 55  
 Gagné N, 177  
 Gangakhedkar RR, 55  
 Garcia P, 143  
 Garrett SB, 166  
 Gaydos C, 55, 519  
 Gaydos JC, 519  
 Gershman KA, 579  
 Gift TL, 232  
 Glass G, 75  
 Gogate AS, 358  
 Goldberg M, 421  
 Golden MR, 543  
 Gollub EL, 265  
 Gorbach PM, 543  
 Gotuzzo E, 103, 115  
 Gourde P, 177  
 Goyzueta G, 103  
 Gray RH, 590  
 Greenblatt RM, 143  
 Green DL, 49  
 Gregg CR, 160  
 Griffin RG, 291  
 Groseclose SL, 339  
 Gross M, 564, 572  
 Gurvey JE, 208
- H**
- Haggitt RC, 564  
 Hagner D, 579  
 Handsfield HH, 228, S21
- H**
- Han Y, 296  
 Harrison A, 152  
 Harwell TS, 265  
 Hawkins RV, 508  
 Heggenhougen HK, 184  
 Hellberg D, 197  
 Henderson S, 303  
 Herrera GA, 431  
 Hillier SL, 96  
 Hipp S, 296  
 Hobbs MM, 381  
 Hoff GL, 291  
 Hoffman I, 381  
 Hoffman V, 82  
 Höjer B, 491  
 Hollins L, 121  
 Holmes KK, 543  
 Hook EW III, 4, 87, 103, 127, 232, 272, 286, 329, 388, 450, 496, 531, 584  
 Hopkins F, 504  
 Horton S, 564  
 Howell MR, 519  
 Hser Y-I, 82  
 Htun Y, 556  
 Hubbard RA, 303  
 Hwang L-Y, 121
- I**
- Irwin DE, 286  
 Irwin KL, 431  
 Ismail M, 137
- J**
- Jackson TP, 96  
 Jaffurs WJ Sr, 303  
 Jang D, 504  
 Jensen RL, 160  
 Johnson AP, 160  
 Johnson RB, 369, 531  
 Joly JR, 410  
 Jones RB, 369, 552  
 Jones SB, 404  
 Jordan NN, 103  
 Juhász J, 177
- K**
- Kahn R, 108  
 Kalibbala S, 590  
 Kambugu F, 483  
 Kassler WJ, 232, 537  
 Katz BP, 26  
 Kaufman JA, 184  
 Kazembe P, 381  
 Kelaghan J, 127, 329, 450  
 Kelley JK, 579  
 Kell P, 531  
 Kelly CW, 564, 572  
 Kendall C, 108  
 Kidula N, 476  
 Kimball AM, 537  
 Kissinger P, 108, 281  
 Klausner JD, 335, 548  
 Kohl KS, 201  
 Koumans EH, 508  
 Koutsky LA, 392  
 Krepel J, 504  
 Krüger Kjaer S, 325  
 Kulasingam S, 166  
 Kyriakis, KP, 43
- L**
- Lafferty WE, 537  
 Lai R, 531  
 Lappin M, 137  
 Larsen SA, 426  
 La Ruche G, 191  
 Laumann EO, 250  
 Lavoie R, 317  
 LeClerc R, 317  
 Lee FK, 329, 426  
 Leone PA, 286  
 Leong MG, 556  
 Levine H, 564  
 Levine WC, 339  
 Leviton LC, 87  
 Lewis LM, 438, 472  
 Li C, 590  
 Li L, 87  
 Limpakarnjanarat K, 67  
 Livengood CH III, 137  
 Ljubicic M, 12  
 Long BJ, 137  
 Lörincz AT, 303  
 Low N, 404  
 Lurie M, 152  
 Lutalo T, 590  
 Lytle CD, 216

**M**

Macaluso M, 4, 127, 329, 450  
 MacCormack R, 537  
 Maguire A, 500  
 Mahony J, 504  
 Malotte K, 584  
 Mangione-Smith R, 309  
 Mann D, S26  
 Mårdh P-A, 197  
 Marquez C, 157  
 Martens MG, 137  
 Martin DH, 286, 369, 531  
 Massanga M, 508  
 Måsse B, 317  
 Mastro TD, 67  
 Mathur U, 143  
 Matson P, 1  
 Maxwell AE, 463  
 McCormack WM, 531  
 McGee ZA, 160  
 McGlynn EA, 309  
 McKee KT Jr, 519  
 McNaim D, 590  
 Meehan MP, 590  
 Mehendale S, 55  
 Meijer CJLM, 325  
 Mertz GJ, 226  
 Messou N, 191  
 Meyerson B, 399  
 Middlekauff SL, 431  
 Middlestadt SE, 584  
 Miller WC, 381  
 Miotti P, 143  
 Miret M, 500  
 Modarress KJ, 303  
 Mogilevskina I, 197  
 Moran J, 508  
 Morar NS, 374  
 Morré SA, 325  
 Morse S, S8, 63  
 Moseley K, 108  
 Mousavi N, 303  
 Msellati P, 191  
 Muic V, 12  
 Munk C, 325  
 Muñoz D, 115  
 Muse A, 296  
 Muth JB, 345  
 Muth SQ, 49, 93, 345  
 Myers L, 281

**N**

Nagelkerke NJD, 33  
 Nahmias A, 329, 426  
 Nelson AL, 137  
 Niccolai LM, 281  
 Nkata E, 381  
 Noba V, 191  
 Nopkesorn T, 67  
 Norris AE, 17  
 Nsubuga PSJ, 483  
 Nuwaha F, 483, 491

**O**

Ogonor JI, 184  
 Okonofua FE, 184  
 O'Leary J, 309  
 Omar RF, 177  
 Ombette J, 476  
 Omega Study Group, 317  
 Omorodion FI, 184  
 Orr DP, 26  
 Otis J, 317

**P**

Paffel J, 121  
 Paradise M, 564  
 Parece MS, 431  
 Parent R, 317  
 Paris M, 103  
 Parker EK, 213  
 Parker KA, 508  
 Pastore LM, 96  
 Patel J, 504  
 Pate MS, 232  
 Piot P, 244  
 Pluck ND, 531  
 Poll PA, 325  
 Potterat JJ, 49, 93, 345  
 Poulin C, 410  
 Pozniak AL, 404

**Q**

Quinn TC, 55, 519, 551, 590

**R**

Rabe LK, 96  
 Rajamanoharan S, 404  
 Rakai Project Team, 590  
 Ramjee G, 374  
 Ramstedt K, 390  
 Rathbun KC, 350  
 Reed AW, 381  
 Reitano M, 364  
 Remis RS, 317  
 Rhodes P, 421  
 Rice J, 108  
 Richards EP III, 350  
 Richey CM, 4, 272, 496  
 Rietmeijer CA, 95, 584  
 Ringuet J, 410  
 Rioux JE, 177  
 Risbud A, 55  
 Risser JMH, 121  
 Risser WL, 121  
 Roberts D, 213  
 Roberts MC, 157  
 Rocha E, 426  
 Rodriguez-Trias H, S48  
 Rompalo A, 55  
 Ronald A, 517  
 Rosenberg D, 108  
 Rosenberg MD, 208  
 Rosen T, 527  
 Rosenthal SL, 438, 472  
 Ross M, 444

Rothenberg RB, 345

Royce RA, 96  
 Rudy B, 265  
 Ryncarz A, 1

**S**

Sagov S, 137  
 Sande J, 476  
 Sangkharomya S, 67  
 Savitz DA, 96  
 Schachter J, 241, 279, S8

**S**

Schmid DS, 67  
 Schwebke JR, 286, 496  
 Scioneaux J, 201  
 Selke S, 221  
 Serwadda D, 590  
 Sewankambo NK, 590  
 Sheehan KL, 137  
 Shepherd ME, 55  
 Shivkar LK, 358  
 Shriver M, S42  
 Siegal HA, 87  
 Silver S, 143  
 Skinner E, 364  
 Somers P, 508  
 Soper DE, 137  
 Spitters CE, 286  
 Sproston A, 504  
 St. Louis ME, 339, 421, 426  
 Stamm WE, 392  
 Stanberry LR, 438, 472  
 Steen R, S12  
 Steiner MJ, 459  
 Stephens J, 272  
 Stergachis A, S44  
 Stern J, 364  
 Stewart FH, S1  
 Stoll BJ, 426  
 Stone KM, 228  
 Stoner B, 584  
 Stratton JD, 286  
 Succop PA, 438, 472  
 Suchland RJ, 392  
 Surawicz C, 564  
 Sweet RL, 137  
 Sylla-Koko F, 191

**T**

Tabet SR, 564, 572  
 Tabidze IL, 426  
 Tambe P, 426  
 Taylor JE, 49  
 Taylor-Robinson D, 160  
 Temin MT, 184  
 Temmerman M, 476  
 Thomas JC, 286  
 Thorp JM, 137  
 Thorp JM Jr, 96  
 Tremblay MJ, 177  
 Trino R, 265  
 Troutman GL, 303

Trovafoxacin Chlamydial Urethritis/Cervicitis Study Group, 531

Trujillo L, 115  
 Turnel B, 317  
 Tyndall MW, 476  
 Tying S, 364  
 Tzelepi E, 43  
 Tzouveleakis LS, 43

**V**

Valappil T, 450  
 Vall Mayans M, 500  
 Van De Laar MJW, 33  
 Van Den Brule AJC, 325  
 Vandevanter N, 584  
 Van Duynhoven YTHP, 33  
 Vermund SH, 103  
 Vincelette J, 317  
 Vodopija I, 12  
 Voigt RF, 431

**W**

Wabwire-Mangen F, 590  
 Waites K, 496  
 Wald A, 1, 364  
 Warda US, 463  
 Warner L, 459  
 Wasserheit JN, 228, 549, S28

**W**

Watts DM, 115  
 Wawer MJ, 590  
 Weber AE, 374  
 Wee S, 593  
 Wellfens-Ekra C, 191  
 Weniger BG, 67  
 White HA, 49  
 White SD, 213  
 Whittington WLH, S43  
 WIHS Collaborative Study Group, 143  
 Wilkinson D, 152  
 Wilkinson TH, 291  
 Williams M, 444  
 Wong ML, 593  
 Woodhouse DE, 345  
 Wools KK, 26  
 Wozniak A, 213  
 Wright JM, 556

**X**

Xia M, 157

**Y**

Yarber WL, 399  
 Yi A, 115  
 Yorkman S, 265  
 Youm Y, 250

**Z**

Zaidi AA, 339  
 Zenilman JM, 75, 286  
 Zimba D, 381  
 Zimmerman-Rogers H, 49

## INDEX OF SUBJECTS

## A

- Abortion, induced, STD occurrence and, 197  
 Accelerated Campaign to Enhance STD Services (ACCESS) for youth, S28, S42  
 Adolescents  
   black/Hispanic, condom use by, 17, 463  
   with chlamydia, gonorrhea, or trichomoniasis, subsequent STDs in, 26  
   concurrent sex partners of, 208  
   female  
     chlamydial infection in, subsequent STDs and, 26  
     chlamydia screening for, health and cost-benefits of, 309  
     locus of control for general health and STD acquisition among, 472  
   incarcerated/detained  
     preventive education for, 265  
     STD screening for, 265  
   STD health care for  
     assessment of, in Nigeria, 184  
     CDC pilot projects for, S28, S42  
 Africa, douching in pregnancy in, STD prevalence and, 191  
 African Americans  
   bacterial vaginosis in  
     genital cleansing practices and, 404  
     in pregnancy, 96  
   young, condom use by, 17, 463  
 AIDS. *See* Human immunodeficiency virus infection  
 Alcohol abuse. *See also* Substance abuse  
   high-risk sexual behavior and, 87  
 Antibiotic resistance, gonococcal, in India, 358  
 Aral, Sevgi, O., ASTDA Achievement Award recipient, 243  
 Army recruits, female, chlamydia control measures for, 519  
 ASTDA Achievement Awards, 243, 551

## B

- Bacterial vaginosis  
   genital cleansing practices and, 404  
   incidence and prevalence estimates for, S2  
   0.75% metronidazole gel for, 137  
   in pregnancy, race/ethnicity and, 96  
 Barrier contraceptives. *See* Condoms  
 Bayes' theorem-based assessment, of VDRL screening miss rates, 12  
 Behavior. *See* Sexual behavior  
 Bites, human penile, genital ulcer due to, 527  
 Blacks. *See* African Americans; Race/ethnicity

## C

- Calendar blister packaging, treatment compliance and, 556  
 Cancer, cervical, in HIV-infected women, 500  
 Centers for Disease Control and Prevention (CDC)  
   pilot projects for adolescent care of, S28, S42  
   prevention agenda for genital herpes of, 228  
 Central African Republic, low-cost care delivery in, 508, 517 (editorial)  
 Cervical cancer, in HIV-infected women, 500  
 Chlamydial infection  
   in adolescents girls, subsequent STDs and, 26  
   doxycycline for, measured vs. self-reported compliance with, 272, 279 (editorial)  
   efficient notification (interview) periods for, 49  
   estimated incidence and prevalence of, in 1996, 339  
   incidence and prevalence estimates for, S2  
   ligase chain reaction testing for, pooled urine specimens for, 504  
   newly available and future laboratory tests for, S8  
   partner notification for, among private sector clinicians, 543  
   PCR-detected, prevalence of and risk factors for, 325  
   point-of-care tests for, 232  
   predictors of, in Kenyan women, 476  
   prevalence of, in injection vs. noninjection drug users, 410  
   recurrent, risk assessment and management for, 4  
   screening for  
     follow-up rates after, 496  
     time to treatment after, 421, 496

- in young women, health and cost-benefits of, 309  
   in sex workers, in Peru, 103  
   specimens for  
     adequacy of, 579  
     stability of during transport, 213  
   trovafloxacin for, 369  
   vs. doxycycline, 531  
*Chlamydia trachomatis*, Hybrid Capture II and PACE 2 nucleic acid probe tests for, 303  
 Ciprofloxacin, gonococcal resistance to, in India, 358  
 Client education. *See* Education  
 Cocaine use. *See also* Substance abuse  
   high-risk sexual behavior and, 82  
   selling of sex and, 444  
 Coital diary, for sexual behavior reporting, vs. recall questionnaire, 374  
 College students, attitudes of toward vaccination for genital herpes, 438  
 Commercial sex workers. *See* Sex workers  
 Compliance  
   calendar blister packaging and, 556  
   measured vs. self-reported, for doxycycline for chlamydial infection, 272, 279 (editorial)  
 Computers  
   HSV preventive education programs for, 364  
   Internet use for health information with, 548 (letter)  
 Concurrent sex partnership, in adolescence, 208  
 Condoms  
   failure of, in high-risk population, 450, 459 (editorial)  
   integrity of, laboratory tests of, 216  
   prophylactic efficacy of, prospective study of, 127  
   use of  
     by black/Hispanic youth, 17, 463  
     by injection drug-using male prostitutes, 93 (letter)  
   self-reported  
     by STD clinic clients, 286  
     validity of, 459 (editorial)  
   by sex workers  
     in Peru, 115  
     in Singapore, 593  
   by Ugandan STD patients, predictors of, 491  
 Core theory dynamics, geographic information system and, 75  
 Core transmission  
   of gonorrhea, field intervention and, 296  
   of syphilis, 108  
 Crack cocaine. *See also* Substance abuse  
   high-risk sexual behavior and, 82  
   selling of sex for, 444

## D

- Developing countries  
   low-cost care delivery in, 508, 517 (editorial)  
   STD syndrome packets for, 152  
 Diary, coital, for sexual behavior reporting, vs. recall questionnaire, 374  
 DNA, HSV, in semen, 1  
 Douching  
   bacterial vaginosis and, 404  
   in pregnant African women, STD prevalence and, 191  
 Doxycycline  
   for chlamydial infection, measured vs. self-reported compliance with, 272, 279 (editorial)  
   vs. trovafloxacin, for chlamydial infection, 531  
 Drug abuse. *See* Substance abuse  
 Drug resistance, gonococcal, in India, 358  
 Drug therapy. *See also* Treatment  
   compliance with  
     calendar blister packaging and, 556  
     measured vs. self-reported, in chlamydial infection, 272, 279 (editorial)

## E

- Education  
 preventive  
   for genital herpes, interactive computer-based program for, 364  
   for incarcerated/detained male adolescents, 265  
   Websites for, 548 (letter)  
 ELISPOT, for syphilis, 426  
 Endocervical specimens, for chlamydial infection  
   adequacy of, 579  
   stability of during transport, 213  
 Enzyme-linked immunosorbent assay (ELISPOT), for syphilis, 426  
 Epidemiologic mass treatment and syndrome management, for STDs, S12, S21  
 Epidemiology  
   geographic information system and, 75  
   of gonorrhea, in Greek males, 43  
   of HSV-2 vs. HIV-1, 67  
   incidence and prevalence estimates in, S2  
   for chlamydial infection, 339  
   social network analysis in, 108, 250, 262 (editorial)  
   of syphilis  
     core transmitters of, 108  
     during waning years of epidemic, 121  
 Ethnicity. *See* Race/ethnicity
- G
- Gay men, hepatitis B vaccination status of, 317  
 Genital cleansing practices  
   bacterial vaginosis and, 404  
   in pregnant African women, STD prevalence and, 191  
 Genital herpes. *See* Herpes simplex virus infection  
 Genital ulcers  
   due to human penile bite, 527  
   etiology of, in India, 55, 63 (editorial)  
   newly available and future laboratory tests for, S8  
 Gen-Probe PACE 2 assay  
   for *C. trachomatis*  
     vs. Hybrid Capture test, 303  
     specimen stability during transport and, 213  
   for *N. gonorrhoeae*, vs. Hybrid Capture test, 303  
 Geographic information system, for epidemiologic studies, 75  
 Gonococcal salpingitis, mucosal TNF- $\alpha$  concentration in, sloughing of  
   ciliated cells and, 157  
 Gonorrhea  
   in adolescents girls, subsequent STDs and, 26  
   core intervention for, 296  
   drug resistance in, in India, 358  
   in Greek males, epidemiology of, 43  
   Hybrid Capture II and PACE 2 nucleic acid probe tests for, 303  
   incidence and prevalence estimates for, S2  
   newly available and future laboratory tests for, S8  
   in Peruvian sex workers, 103  
   predictors of, in Kenyan women, 476  
   prevalence of, in injection vs. noninjection drug users, 410  
   reemergence of in Sweden, 390  
 Greece, male gonorrhea in, epidemiology of, 43

## H

- Haemophilus ducreyi*, newly available and future laboratory tests for, S8  
 Health care, forecast for, S49  
 Health Hold Orders, 345, 350 (editorial)  
 Hepatitis B  
   incidence and prevalence estimates for, S2  
   vaccination for, among male homosexuals, 317  
 Herpes simplex virus DNA, in semen, 1  
 Herpes simplex virus infection  
   CDC prevention agenda for, 228  
   incidence and prevalence estimates for, S2  
   newly available and future laboratory tests for, S8  
   preventive education for, interactive computer-based program for, 364  
   recurrent vs. first-episode, differential diagnosis of, 221, 227 (editorial)

- seroprevalence of in female STD clinic clients, epidemiologic and behavioral correlates of, 329  
 type 2, epidemiology of, vs. of HIV-1, 67  
 vaccination for, college students' attitudes toward, 438  
 High-risk sexual behavior  
   in adolescents, concurrent sex partners and, 208  
   alcohol abuse and, 87  
   cocaine use and, 82  
   condom failure and, 450, 459 (editorial)  
   crack cocaine use and, 444  
   self-reported, by STD clinic clients, 286  
 Hispanics, young, condom use by, 17, 463  
 History. *See* Sexual history  
 Homosexuals, male, hepatitis B vaccination status of, 317  
 Human immunodeficiency virus infection  
   cervical cancer in, 500  
   disclosure of to sexual partners, 281  
   genital ulcer disease and, in India, 55, 63 (editorial)  
   incidence and prevalence estimates for, S2  
   male trichomonal urethritis and, 381, 388 (letter)  
   prevalence of, in injection vs. noninjection drug users, 410  
   prevention of, global priorities for, 244 (Parran Award Lecture)  
   risk for  
     alcohol abuse and, 87  
     cocaine use and, 82  
   in sex workers, in Peru, 115  
   STD incidence and, in infected vs. high-risk uninfected women, 143  
   surveillance programs for, 291  
   testing for, urine vs. serum specimens for, 590  
   type 1, epidemiology of, vs. of HSV-2, 67  
 Human papillomavirus infection, incidence and prevalence estimates for, S2  
 Human T-cell leukemia virus infection, in sex workers, in Peru, 115  
 Hume, John Chandler, 119 (obituary)  
 Hybrid Capture II test, vs. Pace 2 test, 303

## I

- Immunization  
   for genital herpes, college students' attitudes toward, 438  
   for hepatitis B, among male homosexuals, 317  
 Incarcerated/detained persons  
   adolescent male, preventive education for, 265  
   female, in-jail acquisition of trichomoniasis in, 335  
   Health Hold Orders and, 345, 350 (editorial)  
   STD testing policies and practices for, 431  
 Incidence rates. *See* Epidemiology and specific infections  
 India  
   genital ulcer disease in, etiology of, 55, 63 (editorial)  
   *N. gonorrhoeae* auxotypes, serotypes, and drug sensitivity in, 358  
   Information technology, in STD control, S23, S26  
 Injection drug users. *See also* Substance abuse  
   chlamydial, gonococcal, and HIV infection prevalence in, 410  
   incomplete partner notification by, forgetting as cause of, 166  
   male, sex hustling by, 93  
 Internet, use of for health information, 548 (letter)  
 Intravenous drug use. *See* Injection drug use  
 Involuntary detention, for STD testing, 345, 350 (editorial)

## J

- Jails  
   preventive education in, 265  
   STD testing in, 431  
   trichomoniasis acquisition in, 335  
 Jones, Robert B., Thomas Parran Award recipient, 551, 552

## K

- Kenya, predictors of female chlamydial and gonococcal infection in, 476

## L

- Laboratory tests. *See also* specific tests  
   for chlamydial infection  
     endocervical specimen adequacy for, 579  
     in Kenyan women, 476

- pooled urine specimens for, 504
  - specimen adequacy for, 579
  - specimen stability during transport for, 579
  - enzyme-linked immunosorbent assay (ELISPOT), for syphilis, 426
  - for gonococcal infection, in Kenyan women, 476
  - for HIV testing, urine vs. serum specimens for, 590
  - newly available and future, for non-HIV STDs, S8
  - PCR, for chlamydial infection, 325
  - Leukocyte esterase urine dipstick testing, for chlamydial and gonococcal infection, in Kenyan women, 476
  - Ligase chain reaction testing, for chlamydial infections, pooled urine specimens for, 504
  - Locus of control, in female adolescents, STD acquisition and, 472
  - Low-income women, barriers to seeking care among, 399
- M**
- Malawian, trichomonal urethritis in, 381
  - Male prostitution, substance abuse and, 93 (letter)
  - Managed care, information technology in STD control in, S23, S26
  - Metronidazole gel (0.75%), for bacterial vaginosis, 137
  - Military recruits, female, chlamydia control measures for, 519
  - Monogamy, condom use by low-income minority youth and, 17
  - Mucosal toxicity, of nonoxynol-9, reduction of by thermoreversible gel, 177
  - Mucosal tumor necrosis factor- $\alpha$ , in gonococcal salpingitis, sloughing of ciliated cells and, 157
  - Multiplex polymerase chain reaction, for genital ulcer disease diagnosis, in India, 55, 63 (editorial)
- N**
- Neisseria gonorrhoeae*. *See also* Gonorrhea
    - auxotypes, serotypes, and drug sensitivity of, in India, 358
    - Hybrid Capture II and PACE 2 nucleic acid probe tests for, 303
    - 3.05  $\beta$ -lactamase plasmid of, conjugal transfer of, 157
    - newly available and future laboratory tests for, S8
  - Network analysis
    - of racial/ethnic differences in STD prevalence, 108, 262 (editorial)
    - of syphilis transmission, 108
  - Networking, information technology for, in managed care, S23, S26
  - Nigerian adolescents, STD health care for, assessment of, 184
  - Nonoxynol-9
    - mucosal toxicity of, reduction of by thermoreversible gel, 177
    - as rectal microbicide, safety and toxicity of, 564, 572
- P**
- PACE 2 test
    - for *C. trachomatis*
      - vs. Hybrid Capture test, 303
      - specimen stability during transport and, 213
    - for *N. gonorrhoeae*, vs. Hybrid Capture test, 303
  - Packaging, user-friendly, treatment compliance and, 556
  - Parran Award Lectures, 244, 552
  - Partner notification
    - for chlamydial infections
      - among private sector clinicians, 543
      - notification (interview) periods for, 49
    - factors influencing, in Uganda, 483
    - for HIV infection, 281
    - for syphilis control, 201
  - Partner reporting, incomplete, forgetting as cause of, 166
  - Penicillin, gonococcal resistance to, in India, 358
  - Penis, human bite to, genital ulcer due to, 527
  - Peru
    - sex worker in, HIV, HTLV-I/II, and syphilis in, 115
    - sex workers in, gonococcal and chlamydia infections in, 103
  - Pharmacists, in STD prevention and control, S44, S48
  - Piot, Peter, Thomas Parran Award recipient, 243, 244
  - Police power, for involuntary detention for STD testing, 345, 350 (editorial)
  - Polymerase chain reaction
    - for chlamydial infection, prevalence and risk factor correlates for, 325
    - for genital ulcer disease, in India, 55, 63 (editorial)

- Pregnancy
  - bacterial vaginosis in, race/ethnicity and, 96
  - douching in, STD prevalence and, in Africa, 191
- Prevalence rates. *See* Epidemiology and specific infections
- Preventive education
  - for genital herpes, interactive computer-based program for, 364
  - for incarcerated/detained male adolescents, 265
  - Websites for, 548 (letter)
- Prisoners. *See* Incarcerated/detained persons
- Privatization, of STD clinics, quality review for, 537
- Prostitutes. *See* Sex workers

**Q**

- Quality review, for privatized STD clinics, 537
- Questionnaire, recall, for sexual behavior reporting, vs. coital diary, 374
- Quinn, Thomas, ASTDA Achievement Award recipient, 551

**R**

- Race/ethnicity
  - bacterial vaginosis and
    - genital cleansing practices and, 404
    - in pregnancy, 96
  - condom use and, 17, 463
- Rapid tests, for *C. trachomatis* infection, 232, 241 (editorial)
- Recall questionnaire, for sexual behavior reporting, vs. coital diary, 374
- Rectal microbicide, nonoxynol-9 as, safety and toxicity of, 564, 572
- Research, professional relationships in, 552 (Parran Award Lecture)
- Risk factors. *See also* Sexual behavior
  - for chlamydial infection, in Kenyan women, 476
  - for chlamydial reinfection, 4
  - for gonococcal infection, in Kenyan women, 476
  - for HIV infection
    - alcohol abuse as, 87
    - cocaine use as, 82
  - in injection vs. noninjection drug users, 410
  - for PCR-detected chlamydial infection, 325
  - for STDs
    - douching in pregnancy as, in Africa, 191
    - history of induced abortion as, 197
- Risk management strategies, for incarcerated/detained male adolescents, 265

**S**

- Salpingitis, gonococcal, mucosal TNF- $\alpha$  concentration in, sloughing of ciliated cells and, 157
- Screening
  - for chlamydial infection
    - endocervical specimen adequacy for, 579
    - follow-up rates after, 496
    - in Kenyan women, 476
    - rapid tests for, 232, 241 (editorial)
    - time to treatment after, 421, 496
    - in young women, health and cost-benefits of, 309
  - for gonococcal infection, in Kenyan women, 476
  - involuntary detention for, 345, 350 (editorial)
  - in jail populations, 431
  - for syphilis, miss rates for, Bayes' theorem-based assessment of, 12
- Self-reporting
  - of compliance with doxycycline for chlamydial infection, 272, 279 (editorial)
  - of condom use
    - reliability of, 286
    - validity of, 459 (editorial)
  - of sexual behavior, recall questionnaire vs. coital diary for, 374
  - of sexual history, reliability of, 33, 286
- Semen, HSV DNA in, 1
- Serum specimens. *See also* Specimens
  - for HIV testing, vs. urine specimens, 590
- Sex partnership, concurrent, in adolescence, 208
- Sexual behavior
  - of adolescents, concurrent sex partners and, 208



- high-risk
    - in adolescents, concurrent sex partners and, 208
    - alcohol abuse and, 87
    - cocaine use and, 82, 444
    - condom failure and, 450, 459 (editorial)
  - reporting of
    - recall questionnaire vs. coital diary for, 374
    - reliability of, 33, 286
  - of young low-income African Americans/Hispanics, condom use and, 17
  - Sexual history
    - coital diary vs. recall questionnaire for, 374
    - elicitation of, practice patterns for, 584
    - self-reported, reliability of, 33
  - Sexually transmitted disease clinic clients
    - female, HSV seroprevalence in, epidemiologic and behavioral correlates of, 329
    - high-risk sexual behavior of. *See also* Sexual behavior, high-risk
      - cocaine use and, 82
      - self-reported condom use by, 286
      - self-reported high-risk behavior by, 286
  - Sexually transmitted disease clinics
    - low-cost care delivery in, in Central African Republic, 508, 517 (editorial)
    - privatized, quality review of, 537
    - quality of care in, for Nigerian adolescents, 184
  - Sexually transmitted diseases. *See also specific diseases*
    - acquisition of, female adolescent locus of control and, 472
    - among HIV-infected vs. high-risk uninfected women, 143
    - barriers to seeking care for, 399
    - control of
      - future directions in, 549
      - information technology in, S23, S26
      - pharmacists' role in, S44, S48
    - epidemiologic mass treatment and syndrome management for, S12, S21
    - incidence and prevalence estimates for, S2
    - non-HIV, newly available and future laboratory tests for, S8
    - prevalence of, racial/ethnic group differences in, 250
    - research in, professional relationships in, 552 (Parran Award Lecture)
    - risk of. *See* Risk factors
    - subsequent, in adolescents with chlamydia, gonorrhea, or trichomoniasis, 26
    - testing for. *See* Laboratory tests; Screening
    - treatment of. *See* Treatment
  - Sexually Transmitted Diseases*, most frequently cited article from, 549
  - Sexually transmitted disease syndrome packets, 152
    - calendar blister packaging for, 556
  - Sexual network analysis. *See* Social network analysis
  - Sexual partnerships. *See also* under Partner
    - geography of, core theory dynamics and, 75
  - Sex workers
    - condom use by
      - in Peru, 115
      - in Singapore, 593
    - gonococcal and chlamydial infections in, in Peru, 103
    - HIV, HTLV-I/II, and syphilis in, in Peru, 115
    - involuntary detention of, for STD testing, 345, 350 (editorial)
    - male, substance abuse by, 93 (letter)
    - sex selling for drugs by, 444
    - sexual behavior reporting by, recall questionnaire vs. coital diary for, 374
  - Singapore, condom use by sex workers in, 593
  - Social network analysis
    - of racial/ethnic differences in STD prevalence, 108, 262 (editorial)
    - of syphilis transmission, 108
  - Spain, cervical cancer in HIV-infected women in, 500
  - Specimens
    - endocervical chlamydial
      - adequacy of, 579
      - stability of during transport, 213
    - pooled urine, for ligase chain reaction testing for *C. trachomatis*, 504
    - urine vs. serum, for HIV testing, 590
  - Spermicides
    - mucosal toxicity of, reduction of by thermoreversible gel, 177
    - as rectal microbicides, safety and toxicity of, 564, 572
  - STD Forum: Conspiracy to Innovate
    - goals of, S1
    - papers presented at, S2-S50
  - Students, attitudes of toward vaccination for genital herpes, 438
  - Substance abuse
    - chlamydial, gonococcal, and HIV infection prevalence and, 410
    - high-risk sexual behavior and, 82
      - in DIU offenders, 87
      - in STD clinic clients, 82
      - in substance abusers, 444
    - incomplete partner reporting for, forgetting as cause of, 166
    - male prostitution and, 93 (letter)
    - selling of sex and, 444
  - Surveillance, for HIV infection, 291
  - Sweden, gonorrhea reemergence in, 390
  - Syphilis
    - core transmission of, 108
    - enzyme-linked immunosorbent assay (ELISPOT) for, 426
    - epidemiology of, during waning years of epidemic, 121
    - incidence and prevalence estimates for, S2
    - newly available and future laboratory tests for, S8
    - partner notification for, 201
    - in sex workers, in Peru, 115
    - VDRL test for, miss rates for, Bayes' theorem-based assessment of, 12
- T**
- Tetracycline, gonococcal resistance to, in India, 358
  - Third-world countries
    - low-cost care delivery in, 508, 517 (editorial)
    - STD syndrome packets for, 152
  - Thomas Parran Award Lectures, 244, 552
  - Transport, of *C. trachomatis* specimens, 213
  - Treatment
    - barriers to seeking, 399
    - low-cost delivery of, in Central African Republic, 508, 517 (editorial)
    - in Nigerian adolescents, quality assessment for, 184
    - presumptive, S21
    - STD syndrome packets for, 152
  - Treatment compliance
    - calendar blister packaging and, 556
    - measured vs. self-reported, for doxycycline for chlamydial infection, 272, 279 (editorial)
  - Treponema pallidum*. *See also* Syphilis
    - newly available and future laboratory tests for, S8
  - Trichomonas vaginalis* infection
    - in adolescents girls, subsequent STDs and, 26
    - incidence, diagnosis, and treatment of, 388 (letter)
    - incidence and prevalence estimates for, S2
    - in-jail acquisition of, 335
  - Trichomonas vaginalis* urethritis, in Malawian men, 381
  - Trovaflaxacin
    - for chlamydial infections, 369
    - vs. doxycycline, for chlamydial infection, 531
  - Tumor necrosis factor- $\alpha$ , in gonococcal salpingitis, sloughing of ciliated cells and, 157
- U**
- Uganda
    - condom use by STD patients in, predictors of, 491
    - partner referral in, factors influencing, 483
  - Ulcers. *See* Genital ulcers
  - University students, attitudes of toward vaccination for genital herpes, 438
  - Urethritis, trichomonal, in Malawian men, 381
  - Urine specimens
    - for HIV testing, vs. serum specimens, 590
    - pooled, for ligase chain reaction testing, for chlamydial infections, 504

User-friendly packaging, treatment compliance and, 556

## V

### Vaccination

- for genital herpes, college students' attitudes toward, 438
- for hepatitis B, among male homosexuals, 317

### Vaginal cleansing practices

- bacterial vaginosis and, 404
- in pregnant African women, STD prevalence and, 191

### Vaginosis. *See* Bacterial vaginosis

VDRL test, miss rates for, Bayes' theorem-based assessment of, 12

Viruses, condom penetration by, laboratory tests and, 216

## W

Water leak test, for condoms, efficacy of, 216

Websites, use of for health information, 548 (letter)

Wounds, human bite, of penis, genital ulcer and, 527

## Y

### Young adults

- attitudes of toward vaccination for genital herpes, 438
- low-income African American/Hispanic, condom use by, 17